Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,018actual
Sites
37
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-15 | actual | When the study began enrolling |
| Primary completion | 2025-09-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-05 | actual | The whole study's end, after follow-up |
| First posted | 2020-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Prostate Cancer
Primary outcome
what the primary-completion date above is the date OFNumber and percentage of patients with AEs as well as number of AE events as assessed by CTCAE
measured from the time of signature of informed consent, throughout the treatment period and until the end of study follow-up, up to 6 months for Cohort OC, 12 months for Cohort PC after enrolment.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed